IP Library Granted Patent US 7,597,877
Granted Patent B2
US 7,597,877 · App. 10/071,505 · Granted Oct 6, 2009

Administering a gravity segregation dispersion by continuous infusion

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,597,877
App. No.
10/071,505
Granted
Oct 6, 2009
Kind
B2
Abstract

Method and apparatus for continuous infusion to a subject of dispersions in which the dispersed phase is susceptible to flotation or sedimentation. The dispersion is controllably delivered from an upper or lower extremity of an essentially vertically positioned delivery vessel, e.g. syringe 2 , and is then admixed with flushing medium, e.g. from infusion minibag 8 , prior to administration to the subject. Vertical positioning of the delivery device maximises the distance through which flotation or sedimentation may occur, thereby substantially reducing the effects of separation over a given period of time compared to use of a corresponding horizontal delivery vessel such as a syringe placed in a conventional syringe driver.

Claims (8)

1. A method of administering a gas-containing contrast agent to a subject by continuous infusion, the improvement comprising enhancing product homogeneity by controllably delivering said gas-containing contrast agent from an upper extremity of an essentially vertically positioned syringe and admixing with a flushing medium prior to administration to the subject, delivering the admixed product to the subject over an infusion period of 5-60 minutes.

2. The method of claim 1 wherein delivery of said gas-containing contrast agent from said syringe is controlled by a syringe driver.

3. The method of claim 1 wherein said gas comprises sulphur hexafluoride or a perfluorinated low molecular weight hydrocarbon.

4. The method of claim 3 wherein said perfluorinated hydrocarbon is perfluoropropane or perfluorobutane.

5. The method of claim 1 wherein said gas is present as albumin-stabilised microbubbles.

6. The method of claim 1 wherein said flushing medium is normal saline.

7. The method of claim 1 wherein the admixed gas-containing contrast agent and flushing medium are administered by injection.

8. The method of claim 1 wherein the flushing medium is administered at a flow rate of 0.5-5 ml/minute.

Assignments (2)
CHANGE OF NAME Recorded Aug 2, 2006
From: AMERSHAM HEALTH AS; NYCOMED IMAGING AS
To: GE HEALTHCARE AS
Reel/Frame 018039/0537 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2002
From: HENRIKSEN, INGRID; OMTVEIT, TORE; KASPARKOVA, VERA; FAHLVIK, ANNE KJERSTI
To: AMERSHAM HEALTH AS
Reel/Frame 012893/0642 →